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Abstract  
Chlamydia trachomatis is a significant human pathogen with high prevalence and 
potentially severe disease sequelae including infertility. A successful vaccine will 
need to effectively target a combination of humoral and cell-mediated immunity to 
the genital mucosa. Intranasal immunization can effectively target the genital 
tract, but the potent mucosal toxin-based adjuvants such as cholera toxin (CT) 
can cause neurological side effects. CTA1-DD is a non-toxic potent mucosal 
adjuvant which combines the enzymatic properties of CT, with a B cell targeting 
moiety. This adjuvant is able to enhance a mixture of Th1/Th2 responses in the 
mucosal surfaces of the gut and respiratory epithelia. Here, we demonstrate that 
intranasal immunization with CTA1-DD and chlamydial Major Outer Membrane 
Protein results in the induction of neutralizing systemic and mucosal antibodies, 
and is able to enhance protection against a live intravaginal challenge with 
Chlamydia muridarum. 
 
Introduction 
 
Chlamydia trachomatis infections are prevalent worldwide and are responsible 
for severe disease sequelae in the reproductive tracts of both males and 
females, potentially affecting fertility (reviewed in [1,2]). The prevalence of these 
infections is increasing, and associated reproductive disease poses a huge 
burden on the economy [3]. While treatment can be initiated and immediately 
effective, perhaps more than half of all cases are asymptomatic and go 
undetected (reviewed in [4,5]). Furthermore, early treatment intervention 
programs can actually increase overall prevalence over time, associated with an 
increase in susceptibility to secondary infections [6]. Thus, the need for a 
chlamydial vaccine is undeniable.  
 
A successful vaccine against Chlamydia trachomatis infections would need to 
generate significant antibody and cell-mediated immune responses in the genital 
mucosa to target both the extracellular Elementary body and the intracellular 
Reticulate body respectively [7]. Intranasal (IN) immunisation effectively targets 
antigens to the nasal-associated lymphoid tissues [8], and enhances immunity in 
the genital tract via the common mucosal immune system [9]. Previous studies 
have indicated that IN vaccination provides a potent means of targeting 
protective immunity against sexually transmitted infections to the reproductive 
tracts of both females and males [10-12]. The benefits of a mucosal vaccination 
strategy include the potential for self-administration, and the use of non-needle 
delivery strategies.  
 A number of adjuvants that are able to induce mucosal immunity are in use in 
veterinary practice [13], but few have been tested in humans to date. IN 
immunisation with inactivated influenza vaccine and E.Coli heat-labile toxin (LT) 
as an adjuvant resulted in patients having a 19-fold greater risk of developing 
Bell’s palsy than unimmunised patients [14]. Another toxin-based adjuvant, 
cholera toxin (CT) accumulates in the olfactory nerve and bulb of mice [15], as 
the B subunits of CT and LT bind ganglioside receptors present on all nucleated 
cells [16]. Thus the use of these agents in human vaccine formulations is 
currently avoided. 
 
Due to the excellent mucosal adjuvant properties of CT and LT, efforts have 
been made to develop toxin-based adjuvants with improved safety. CTA1-DD is 
one such adjuvant, constructed of the A1 subunit of CT directly linked to a dimer 
of the B cell targeting moiety D, from Staphylococcus aureus protein A [17]. The 
adjuvanticity of CTA1-DD is dependent on the ADP-ribosylating activity of the 
CT-A1 subunit, and requires direct binding to immunoglobulin on B cells [18,19]. 
This adjuvant is capable of homing to the mucosal lining near the NALT at a 
similar time frame to CT [20], and has comparable adjuvanticity [17]. 
Furthermore, unlike CT or LT, CTA1-DD is safe for use, as it does not 
accumulate in the olfactory bulbs of mice following IN immunisation [20]. In vitro 
experiments using human peripheral blood lymphocytes indicate that CTA1-DD 
is also able to augment the expansion of human B cells as it does in mice [21].  
 Due to its safety and strong adjuvant properties, CTA1-DD is considered a 
potential mucosal adjuvant for future use in humans. A number of studies in mice 
have demonstrated its capacity to induce strong mixed Th1/Th2 immune 
responses at the lung and gut mucosa when co-administered with antigen and 
delivered by the IN route. This immunity has resulted in enhanced protection 
against a number of pathogens including influenza virus, rotavirus and 
Helicobacter pylori [22-24]. However, the capacity of CTA1-DD to enhance 
mucosal immunity within the genital tract has not yet been examined. Here we 
demonstrate the first evidence that CTA1-DD immunisation by the IN route is 
able to induce immunity in the reproductive tract. IN immunisation with 
chlamydial Major Outer Membrane Protein (MOMP) co-administered with CTA1-
DD results in the strong induction of neutralising systemic and mucosal 
antibodies, and enhances protection against a live challenge with Chlamydia 
muridarum, the murine model for Chlamydia trachomatis infection. 
Materials and Methods 
 
Mice, antigen, adjuvant and Chlamydia muridarum 
Female BALB/c mice were obtained from the Animal Resources Centre (Perth, 
Australia). Mice were provided with sterile food and water ad libitum, and were 
maintained under specific pathogen free conditions. All procedures were 
approved by the Queensland University of Technology Animal Ethics Committee. 
The transformed E.coli DH5α(pMMM3) expressing the pMAL-c2 vector encoding 
recombinant maltose binding protein-major outer membrane protein (MOMP) of 
Chlamydia muridarum was a generous gift from Harlan Caldwell (Rocky 
Mountain Laboratories, Hamilton, Montana) and recombinant protein was 
prepared as previously described [12,25]. CTA1-DD was prepared as previously 
described [17] and provided by Nils Lycke. Chlamydia muridarum (C.mu)  was 
obtained from  the ATCC (VR-123) and was propagated in McCoy cells.  
 
Intranasal Immunization 
Groups of five mice were immunized by the intranasal (IN) route with CTA1-DD 
(20µg) adjuvant alone, 100µg MOMP alone, or CTA1-DD and MOMP in 
combination. The immunization solution was administered to the external nares 
in a 5µl volume per nare, under isofluorane anaesthesia. Immunization occurred 
on days 0, 7 and 14, and animals were boosted on day 35. Serum and lavage 
samples were collected at sacrifice one week following the final boost according 
to the methods described in Hickey et al.[12]. Briefly, serum was separated from 
cardiac puncture blood by centrifugation. Vaginal lavage was obtained by 
flushing the vagina with 40µl sterile PBS. Uterine lavage was collected by 
excising the uterine horn at the level of the uterine corpus and removing the 
ovaries/oviducts, then flushing the horn with 100µl sterile PBS. All samples were 
stored at -20°C prior to analysis.  
 
Examination of systemic and mucosal MOMP-specific antibodies 
MOMP-specific IgG subtype (IgG1 and IgG2a) titres were determined for serum 
samples using the ELISA methods described in Hickey et al.[12]. Vaginal lavage 
and uterine lavage were analysed for MOMP-specific IgA. Greiner medium-
binding 96-well ELISA plates (Greiner Bio-One, FL, USA) were coated with 
2µg/well MOMP. Lavage samples were serially diluted two-fold from 1/20 to 
1/2560 in PBS-Tween, while serum was diluted 1/100 to 1/800,000 for analysis. 
The primary antibodies, biotin-conjugated anti-IgG1, anti-IgG2a and anti-IgA, and 
the secondary Streptavidin-HRP conjugate were all used at a dilution of 1/1000 
(Southern Biotechnology Associates, Birmingham AL). The plates were 
developed using 0.1µg/ml Tetramethyl-benzidine (TMB, Sigma-Aldrich) in 
phosphate citrate buffer (PCB, Sigma-Aldrich), then stopped by the addition of 
1M sulfuric acid. Absorbance of each sample was determined at 450nm and end-
point titre (EPT) was defined as the mean dilution at which the absorbance 
reached that of negative samples (mean PBS sample absorbance + 2 SD).  
 
Neutralization of Chlamydia muridarum in vitro 
To investigate the Chlamydia-neutralizing capacity of these MOMP-specific 
antibodies, the serum and vaginal lavage samples were then examined by in 
vitro neutralization assay on McCoy cells. Tubes containing 5 x 104 inclusion 
forming units (ifu) of C.mu were incubated with two-fold serial dilutions of sample 
for 1h at 37°C before addition to McCoy cell monolayers in 48-well plates in 
triplicate (1/10 to 1/1280 for vaginal lavage, 1/20 to 1/2560 for serum). The plates 
were then incubated for 4h before replacing sample with 500µl Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 5% FCS and 1µg/ml 
cycloheximide (Sigma-Aldrich). Infection was then stopped 36h post-inoculation. 
Chlamydial inclusions were stained using the Chlamydia Cel LPS staining kit 
(CelLabs Brookvale, Australia) and enumerated by microscopy. Percent 
neutralization was determined by comparison to wells inoculated with C.mu 
alone. 
 
Challenge with Chlamydia muridarum and monitoring of clearance 
One week following the final boost, groups of five immunized/naïve mice were 
pretreated with 2.5mg progesterone, then challenged one week later under 
ketamine/xylazine anaesthesia. Challenge was via direct inoculation of the 
vaginal vault with 5 x 104ifu C.mu. Vaginal swabs (Copan nasopharyngeal 
swabs; Interpath, Australia) were taken every three days up to day 21. Swabs 
were placed in 500µl SPG solution and stored at -80°C. Mice were sacrificed at 
day 35 post-infection and gross pathology of the reproductive tract observed. 
DNA was extracted from swab samples using the Amplicor CT/NG specimen 
preparation kit (Roche, Castle Hill, Australia) according to manufacturer’s 
instructions. Real-time PCR to determine chlamydial DNA load in swabs was 
performed using flanking nucleotide primers specific for C.mu MOMP (Forward: 
5’-gcc gtt ttg ggt tct gct t-3’; Reverse: 5’-cgt caa tca taa ggc ttg gtt ca-3’), and 
Platinum Sybr-Green qPCR Supermix with ROX reference dye (Invitrogen, 
Mount Waverley, Australia). The 25µl reaction volume contained 2µl extracted 
swab DNA and 20mM each primer, and samples were run and analyzed on ABI 
PRISM 7000 sequence detection system (PE Applied Biosystems Inc.)[26]. 
Samples were run in conjunction with a series of standards. Results presented 
are representative of two separate experiments, and are expressed as number of 
mice positive for infection. The amounts of shed bacteria between the 
experiments were not directly comparable, so were unable to be compiled 
despite showing the same trends. 
  
Statistics 
All graphical data are presented as means and SEM. Statistical analyses were 
performed using GraphPad Prism version 4.0b for Windows (GraphPad 
Software, San Diego California USA). For ELISA, differences between groups 
were examined by unpaired two-tailed t-test. In vitro neutralization assays and 
swab clearance were analysed by two-way repeated measures ANOVA with 
Bonferroni post-test. Significant differences are denoted as *p=0.05 to 0.01, 
**p=0.01 to 0.001, ***p<0.001. 
Results and discussion 
 
MOMP-specific antibodies in serum 
IN immunization with CTA1-DD and MOMP resulted in the induction of extremely 
high levels of circulating IgG antibodies against MOMP (Fig1A). Somewhat 
unexpectedly, these were no higher than the antibody level induced by IN 
immunization with MOMP alone, thus it is not possible to determine if this 
immunization is enhancing Th1 or Th2 responses preferentially. Similar results 
were found by Akhiani et al. [27] who observed only mild increases in specific 
IgG1 and IgG2a responses when CTA1-DD was added to their IN immunization 
with Helicobacter pylori sonicate [27]. However others have found that the 
addition of CTA1-DD to antigen can strongly preferentially stimulate an increase 
in IgG1 denoting a Th2 response [24,28], or an increase in IgG2a denoting a Th1 
response [22]. This variable response does not result from the studies being 
performed in different species of mice, and thus the co-administered antigen 
must have a role in driving the specific arm of the immune response.   
 
Interestingly despite having similar levels of IgG antibodies, the IN immunization 
incorporating CTA1-DD was able to induce significantly greater neutralization of 
chlamydial elementary bodies in vitro than immunization with MOMP alone; 68% 
versus 14% neutralization with a 1/20 dilution of serum sample (Fig1B). The 
reason for this is uncertain, but could possibly result from CTA1-DD directing 
immune responses against a different epitope of the MOMP protein, somehow 
via their direct interaction with B cells. Another possibility is that antigen 
recognition occurs in a different manner when CTA1-DD is present. In one study, 
20ug CTA1-DD gave significant anti-CTA1 titres in serum and broncho-alveolar 
lavage, while the adjuvant properties were unaffected [29]. It was proposed that 
this adjuvant promotes immunity to the co-administered antigen by anti-CTA1 
binding to CTA1DD and increasing Fc-receptor-mediated uptake processes [30]. 
I think I need a bit of help with this paragraph please!  
 
Mucosal reproductive tract antibodies 
High levels of MOMP-specific antibodies were induced in the reproductive tracts 
of mice immunized with CTA1-DD and MOMP, with high titres of IgA detected in 
the vaginal lavage and uterine lavage (Fig2). High levels of MOMP-specific IgG 
were also present (data not shown). A one in ten dilution of antibodies in vaginal 
lavage samples from mice receiving CTA1-DD and MOMP was able to neutralize 
infectivity of C.mu by 34%, while vaginal lavage of control groups was unable to 
prevent the infection of McCoy cells. This is the first report of CTA1-DD inducing 
high levels of neutralizing antibodies in the reproductive tract. In fact, in both 
systemic and mucosal samples, immunization with CTA1-DD and MOMP was 
able to generate over four times more antibodies than IN immunization with 
MOMP and a mixture of the adjuvants CT and CpG (data not shown).  
 
This induction of strong neutralizing immunity in the reproductive tract using 
CTA1-DD as an adjuvant has promising implications for a whole host of 
reproductive pathogens. It has previously been shown effective as an adjuvant 
against respiratory and gastrointestinal viral infections [22-24,31], but this report 
suggests that CTA1-DD could also be useful for a range of bacterial and viral 
sexually transmitted infections.  
 
Clearance of Chlamydia from the lower reproductive tract 
Immunization with MOMP and CTA1-DD resulted in fewer mice infected from day 
12 onwards compared to the control groups (Table 1), and a trend for lower 
levels of shed Chlamydia, as shown by McCoy cell culture on swab samples 
(data not shown).  Thus immunizing with CTA1-DD in combination with the 
antigen has conferred some level of protective immunity, and demonstrated a 
trend of reduced upper reproductive tract pathology as determined by diameter of 
oviduct dilation (data not shown). The addition of CTA1-DD in some mouse 
immunization models has resulted in almost complete protection against oral or 
respiratory challenge with pathogen [22,24], however, this level of protection is 
not seen in our model. Immunization studies utilizing  MOMP as an antigen show 
varying levels of protection against an intra-vaginal challenge with Chlamydia 
[32-34]. It is now relatively well accepted that MOMP as a sole antigen will be 
insufficient to induce complete protective immunity against multiple serovars of 
Chlamydia. Recent studies have indicated the potential use of novel protective 
antigens including NrdB, CT0512, and CPAF [35-37]. Further studies will need to 
investigate the protection afforded by such antigens, perhaps as a multi-subunit 
vaccine formulation, using a suitable delivery route and adjuvant to target 
enhanced protective immunity to the genital mucosa, such as the immunization 
strategy presented in this report.  
 
Recent studies have also demonstrated that direct fusion of antigen/s with CTA1-
DD can result in enhanced immunity and protection against challenge [31], while 
combining antigen with CTA1-DD and ISCOMS enhances immune induction 10-
fold [38]. ISCOMS target dendritic cells and possibly macrophages, while CTA1-
DD targets antigen to B cells, thus three different types of antigen presenting 
cells can be utilised [38]. A strong induction of neutralizing antibodies, and 
reduced numbers of infected mice in response to CTA1-DD and MOMP has been 
presented in this study, and here we demonstrate for the first time, the 
compelling potential of this adjuvant for the safe targeting of vaccines against 
reproductive pathogens. 
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Figure legends 
 
Fig 1:  Quantitation of neutralizing MOMP-specific IgG in serum. One week post-
boost serum samples were collected from five mice per group, and ELISA 
conducted to determine levels of MOMP-specific IgG1 and IgG2a (A). 
Absorbance at 450nm was measured and end point titre determined, with t-tests 
to determine significance. Data presented are representative of two separate 
experiments. McCoy cell monolayers were inoculated with 5 x 104 ifu C.mu pre-
incubated with serial dilutions of serum to examine in vitro neutralization (B). 
Infection proceeded for 36h before cells were fixed and stained. Percentage 
neutralization with respect to no serum controls was calculated and significance 
compared to non-immune serum determined by two-way repeated measures 
ANOVA with Bonferroni post-test. *p=0.05 to 0.01, **p=0.01 to 0.001, ***p<0.001. 
 
Fig 2: Quantitation of neutralizing MOMP-specific IgA in mucosal samples. 
Vaginal lavage and uterine lavage samples were collected from five mice per 
group, and ELISA conducted to determine levels of MOMP-specific IgA (A). 
Absorbance at 450nm was measured and end point titre determined, with t-tests 
to determine significance. Data presented are representative of two separate 
experiments. McCoy cell monolayers were inoculated with 5 x 104 ifu C.mu pre-
incubated with serial dilutions of vaginal lavage to examine in vitro neutralization 
(B). Percentage neutralization with respect to no VL controls was calculated and 
significance compared to non-immune VL determined by two-way repeated 
measures ANOVA with Bonferroni post-test. *p=0.05 to 0.01, **p=0.01 to 0.001, 
***p<0.001. 
 
Table  1: Chlamydial clearance determined by PCR on swab samples. Vaginal 
swabs were collected every three days following intravaginal challenge with 
C.mu. Swab DNA was extracted and chlamydial load determined by Real-Time 
PCR. Results are representative of two separate experiments, and expressed as 
number of mice positive for infection.  
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Table 1 
 
Group Number of mice positive for infection (>100ifu/swab)
3 6 9 12 15 18 21
Non-immune 5 5 5 5 5 3 1
MOMP 5 5 5 4 3 3 0
CTA1DD 5 5 5 5 4 4 0
CTA1DD+MOMP 5 5 5 3 3 1 0  
 
 
 
